Abstract: Neoadjuvant chemotherapy is widely used in the therapy of locally advanced breast cancer. In the recent studies, the expressions of ER, PR and C-erbB-2 in tumor may change in different scheme pre- and post-neoadjuvant chemotherapies for breast cancer. It is obviously changed in the neoadjuvant chemotherapy scheme of anthracyclines and paclitaxel/docetaxel, but hardly changed in anthracycline-based neoadjuvant chemotherapy scheme.

Key words: Breast neoplasms, Neoadjuvant chemotherapy, Receptors, estrogen, Receptors, progesterone, Receptors, erbB-2